Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Recent developments in Hexicon’s project portfolio have been mixed, in our view. While the MunmuBaram project finally received regulatory approval, the Swedish Government rejected two key projects, affecting the valuation negatively. Furthermore, Hexicon is still in need of immediate cash infusion, and we believe it will be difficult for the company to overcome the downward pressure from the expected equity issue, the high cash burn, and the remaining question marks concerning the structure of the MunmuBaram divestment. Against this backdrop, we believe that the near-term risk/reward profile is unfavorable. Consequently, we revise our recommendation to Sell (was Reduce) and lower our target price to SEK 0.14 (was 0.23), reflecting the negative impact of the reduced net capacity in the project portfolio and aligning with our SOTP valuation.

We are discontinuing our coverage of OptiCept as the company has terminated the research service agreement. Consequently, we will no longer be giving a target price (prev. SEK 5.3) or recommendation (prev. Reduce) for the stock. OptiCept is investing in the growth of its patented technology platforms based on Pulsed Electric Fields (PEF) and Vacuum Infusion (VI), which have clear customer benefits and short payback periods. Growth to a larger commercial scale has been slow in recent years, but the success in converting existing pilot projects into concrete orders has clear potential to change this in the coming years. In our view, OptiCept shareholders should pay particular attention to the company's ability to maintain its emerging momentum in FoodTech order intake, as this has a clear impact on how quickly cash flow can become positive.

The target market of Kesko, Tokmanni and Lindex's Stockmann division, i.e. department store and hypermarket chains, posted a 2.4% increase in revenue after a sluggish September. Growth was driven by food product groups (4.9%), while durable goods (-3.1%) continued their downward trend.

We are discontinuing our coverage of SciBase as the company has terminated the research service agreement. Consequently, we will no longer give the stock a target price (prev. 0.45 SEK) or recommendation (prev. Reduce).

Olli Nokso-Koivisto, CEO; Jasper Witte Sales Director, Netherlands and Miikka Haavisto, Director of Business Development, Enterprise Sales talk about LeadDesk as an investment.

Hexicons VD Marcus Thor intervjuas av analytiker Lucas Mattsson om Q3 rapporten från Hexicon som publicerades idag. Marcus sammanfattar det tredje kvartalet, pratar om åtgärdsplanen och även hur regeringsbeslutet i Sverige kom som en överraskning.

In the coming year, companies should be able to see who has adapted to the changing market situation and whose strategy is working.

Solwers publicerade sin rapport för det tredje kvartalet den 29/11. I intervjun berättar VD Stefan Nyström vad Solwers gör och pratar om Q3-rapporten. Han pratar även om expansionen till Polen, bolagets förvärv och framtidsutsikter.

While Verve's Q3 revenue aligned with our estimates, adjusted operating profit fell short of expectations. However, the company demonstrated strong cash conversion, and other KPIs remained robust.